U.S. markets closed
  • S&P Futures

    3,894.25
    -4.50 (-0.12%)
     
  • Dow Futures

    31,465.00
    -44.00 (-0.14%)
     
  • Nasdaq Futures

    13,276.50
    -3.25 (-0.02%)
     
  • Russell 2000 Futures

    2,270.40
    -4.40 (-0.19%)
     
  • Crude Oil

    59.70
    -0.94 (-1.55%)
     
  • Gold

    1,708.20
    -14.80 (-0.86%)
     
  • Silver

    26.16
    -0.52 (-1.96%)
     
  • EUR/USD

    1.2038
    -0.0022 (-0.18%)
     
  • 10-Yr Bond

    1.4460
    -0.0140 (-0.96%)
     
  • Vix

    23.35
    -4.60 (-16.46%)
     
  • GBP/USD

    1.3911
    -0.0010 (-0.07%)
     
  • USD/JPY

    106.8700
    +0.1400 (+0.13%)
     
  • BTC-USD

    49,163.70
    +2,890.06 (+6.25%)
     
  • CMC Crypto 200

    984.95
    +56.72 (+6.11%)
     
  • FTSE 100

    6,588.53
    +105.10 (+1.62%)
     
  • Nikkei 225

    29,642.20
    -21.30 (-0.07%)
     

Autolus Therapeutics to participate in Investor Conferences through January

  • Oops!
    Something went wrong.
    Please try again later.
Autolus Limited
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in investor conferences through January 2021.

  • 11 January 2021 – The company will present at the H.C. Wainwright BioConnect 2021 Conference which will be available on demand as of 6:00 am ET, 11 am GMT on Monday, January 11, 2021. The webcast will be available on the investor relations section of the Company’s website at Autolus.

  • 13 January 2021 – The company will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 9:10 am ET, 2.10 pm GMT. The Company will host virtual one-on-one meetings at the J.P. Morgan event and a live audio webcast will be available on the investor relations section of the Company’s website at Autolus.

Archived replays will be available for a period of 30 days after the conferences.

About Autolus Therapeutics plc

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information please visit www.autolus.com.

Contact:

Lucinda Crabtree, PhD
Vice President, Investor Relations and Corporate Communications
+44 (0) 7587 372 619
l.crabtree@autolus.com

Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com

Susan A. Noonan
S.A. Noonan Communications
+1-212-966-3650
susan@sanoonan.com